GoAI
Get started
Prenetics Global Limited logo

Prenetics Global Limited

PRE

NASDAQHealthcareMedical - Diagnostics & Research

Open in GoAI

Previous close

$20.20

+$2.23 · +12.41%

Aug 21, 4:00 PM ET

PRE company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

74

Undervalued

Momentum

47

Neutral

Sentiment

43

Mixed

Risk resilience

50

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

As an investment holding company, Prenetics Global Limited specializes in providing diagnostic and genetic testing services. Its comprehensive product line features CircleDNA, a consumer-oriented genetic analysis solution, and the Circle HealthPod, an advanced health monitoring device. The Circle HealthPod facilitates rapid COVID-19 detection through nucleic acid amplification technology, suitable for both professional point-of-care and personal at-home use. Additionally, the company offers ColoClear, a non-invasive FIT-DNA screening test for colorectal cancer, and Circle SnapShot, a readily available at-home blood testing kit. Other diagnostic solutions in their portfolio include Circle Medical, Circle One, and F1x/Fem. Prenetics Global Limited was founded in 2014 and maintains its headquarters in Quarry Bay, Hong Kong.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
HK
CEO
Sheng Wu Yeung
Listed since
Jul 16, 2021
Employees
98

Market position

Day range

Current $20.20

52-week range

Current $20.20

Open
$17.90
Previous close
$17.97
Volume
329.14K
1.53× average
Average volume
214.44K
Average daily volume
Market cap
343.41M USD
Beta
0.25
Market reference 1
50-day average
$19.1442
+5.51% above average
200-day average
$17.7847
+13.58% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
191.41M USD
P/E (TTM)
-4.86×
P/B (TTM)
3.75×
P/S (TTM)
2.41×
EV / EBITDA
-5.95×
Earnings yield
-17.04%
Free cash flow yield
-9.95%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
62.61%
Operating margin
-35.20%
Net margin
-47.43%
Return on equity
-21.60%
Return on assets
-18.53%
Return on invested capital
-21.52%

Financial health

Debt / equity
0.01×
Current ratio
3.01×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends203%-397%-997%-1597%Gross margin, FY2021: 28.75%Gross margin, FY2022: 27.48%Gross margin, FY2023: 40.61%Gross margin, FY2024: 50.29%Gross margin, FY2025: 52.81%Operating margin, FY2021: -452.11%Operating margin, FY2022: -501.53%Operating margin, FY2023: -238.73%Operating margin, FY2024: -157.23%Operating margin, FY2025: -41.27%Net margin, FY2021: -1388.44%Net margin, FY2022: -1446.78%Net margin, FY2023: -288.48%Net margin, FY2024: -151.22%Net margin, FY2025: -40.82%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 28.75%. Gross margin FY2022 27.48%. Gross margin FY2023 40.61%. Gross margin FY2024 50.29%. Gross margin FY2025 52.81%. Operating margin FY2021 -452.11%. Operating margin FY2022 -501.53%. Operating margin FY2023 -238.73%. Operating margin FY2024 -157.23%. Operating margin FY2025 -41.27%. Net margin FY2021 -1388.44%. Net margin FY2022 -1446.78%. Net margin FY2023 -288.48%. Net margin FY2024 -151.22%. Net margin FY2025 -40.82%.

Income trends

Revenue

92.39M USD+201.72%

Operating income

−38.13M USD+20.80%

Net income

−37.71M USD+18.56%
Income trends across reported periods120.67M USD7.54M USD−105.6M USD−218.74M USDRevenue, FY2021: 12.53M USDRevenue, FY2022: 13.16M USDRevenue, FY2023: 21.74M USDRevenue, FY2024: 30.62M USDRevenue, FY2025: 92.39M USDOperating income, FY2021: −56.66M USDOperating income, FY2022: −66.02M USDOperating income, FY2023: −51.91M USDOperating income, FY2024: −48.14M USDOperating income, FY2025: −38.13M USDNet income, FY2021: −174.01M USDNet income, FY2022: −190.45M USDNet income, FY2023: −62.72M USDNet income, FY2024: −46.3M USDNet income, FY2025: −37.71M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 12.53M USD. Revenue FY2022 13.16M USD. Revenue FY2023 21.74M USD. Revenue FY2024 30.62M USD. Revenue FY2025 92.39M USD. Operating income FY2021 −56.66M USD. Operating income FY2022 −66.02M USD. Operating income FY2023 −51.91M USD. Operating income FY2024 −48.14M USD. Operating income FY2025 −38.13M USD. Net income FY2021 −174.01M USD. Net income FY2022 −190.45M USD. Net income FY2023 −62.72M USD. Net income FY2024 −46.3M USD. Net income FY2025 −37.71M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue92.39M USD30.62M USD21.74M USD13.16M USD12.53M USD
Cost of goods sold43.6M USD15.22M USD12.91M USD9.55M USD8.93M USD
Gross profit48.79M USD15.4M USD8.83M USD3.62M USD3.6M USD
Research and development5.13M USD10.92M USD11.66M USD5.99M USD6.39M USD
Selling, general, and administrative79.8M USD55.37M USD49.68M USD64.08M USD53.67M USD
Operating expenses86.92M USD63.54M USD60.74M USD69.64M USD60.26M USD
Interest income1.04M USD2.04M USD3.92M USD472K USD201 USD
Interest expense241K USD203K USD119.66K USD242K USD42.23K USD
Depreciation and amortization3.78M USD5.93M USD7.79M USD7.54M USD7.35M USD
Operating income−38.13M USD−48.14M USD−51.91M USD−66.02M USD−56.66M USD
Net income−37.71M USD−46.3M USD−62.72M USD−190.45M USD−174.01M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 5 misses, 1 met estimate
Average EPS surprise
-47.89%
11 comparable reports
Latest EPS result
-0.53
Estimate -0.84 · Beat by 36.90%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.35-0.85-1.35-1.86Q1 '25MissQ2 '25MetQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 5, 2025: actual -0.94, estimate -0.72, surprise -30.56%, Miss. Q2 2025, reported Jun 12, 2025: actual -0.8, estimate -0.8, surprise 0.00%, Met estimate. Q3 2025, reported Sep 12, 2025: actual -0.82, estimate -0.71, surprise -15.49%, Miss. Q4 2025, reported Nov 10, 2025: actual -0.41, estimate -0.55, surprise +25.45%, Beat. Q1 2026, reported Feb 18, 2026: actual -1.75, estimate -0.41, surprise -326.83%, Miss. Q2 2026, reported Jun 10, 2026: actual -1.36, estimate -0.49, surprise -177.55%, Miss. Q3 2026, reported Aug 18, 2026: actual -0.53, estimate -0.84, surprise +36.90%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate -0.59, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates67.31M47.85M28.39M8.93MQ1 '25MissQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 5, 2025: actual 10.5M USD, estimate 12.4M USD, surprise -15.32%, Miss. Q2 2025, reported Jun 12, 2025: actual 17.3M USD, estimate 12M USD, surprise +44.17%, Beat. Q3 2025, reported Sep 12, 2025: actual 17.68M USD, estimate 21.7M USD, surprise -18.53%, Miss. Q4 2025, reported Nov 10, 2025: actual 23.56M USD, estimate 26M USD, surprise -9.40%, Miss. Q1 2026, reported Feb 18, 2026: actual 36.6M USD, estimate 33.43M USD, surprise +9.47%, Beat. Q2 2026, reported Jun 10, 2026: actual 35.95M USD, estimate 36M USD, surprise -0.13%, Miss. Q3 2026, reported Aug 18, 2026: actual 46.49M USD, estimate 49.85M USD, surprise -6.74%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate 63.1M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

2 institutions
BenchmarkmaintainBuy

PRE news

seekingalpha.com

Prenetics Global Limited (PRE) Q2 2026 Earnings Call Transcript

Prenetics Global Limited (PRE) Q2 2026 Earnings Call Transcript

Read source
globenewswire.com

Prenetics' IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year Partnership

— Lily is IM8's first Global Ambassador from film and television, extending a roster built in elite sport into global entertainment and culture — Lily brings a following of more than 33 million across social platforms…

Read source
marketbeat.com

Prenetics Global Q2 Earnings Call Highlights

Prenetics Global NASDAQ: PRE reported second-quarter revenue of $46.5 million, up 29% sequentially and about 3.9 times from a year earlier, as its IM8 supplement business continued to add subscribers and scale marketing…

Read source
globenewswire.com

Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220–230 Million; July Was the First Month of Positive Consolidated Adjusted Free Cash Flow and Expected to Remain Positive for Q3 and Beyond

Prenetics' IM8 Reports Q2 2026 Revenue Growth of 288% YoY; Raises FY 2026 IM8 Revenue Guidance to $220–230 Million; July Was the First Month of Positive Co

Read source
globenewswire.com

Prenetics, Parent of IM8, Appoints II Ranked, Caroline Levy, Veteran Wall Street Consumer Analyst as Independent Director

30+ years as one of Wall Street's top-ranked equity research consumer analysts, including leadership of U.S. consumer research at UBS Caroline will also serve on the Audit Committee, Compensation Committee and Nominating…

Read source
globenewswire.com

Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation

Prenetics to Report Q2 2026 Financial Results on August 18, 2026, Live-Stream Earnings Event on Stocktwits, and Announces Upcoming Conference Participation

Read source

PRE peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding PRE

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR Portfolio Emerging Markets ETF logoState Street SPDR Portfolio Emerging Markets ETFSPEM
Market value
1.11M
Weight
0.01%
AUM
17.57B USD
Expense ratio
0.07%
Price / 1D
$52.38+0.61%
State Street SPDR S&P International Small Cap ETF logoState Street SPDR S&P International Small Cap ETFGWX
Market value
136.9K
Weight
0.01%
AUM
927.26M USD
Expense ratio
0.40%
Price / 1D
$46.205+0.40%
State Street SPDR S&P Emerging Markets Small Cap ETF logoState Street SPDR S&P Emerging Markets Small Cap ETFEWX
Market value
106.3K
Weight
0.02%
AUM
685.65M USD
Expense ratio
0.65%
Price / 1D
$72.22+0.25%

Continue in GoAI

Research PRE

research.disclaimer